PH25396A - Vectors, compounds for expression of human protein c - Google Patents

Vectors, compounds for expression of human protein c

Info

Publication number
PH25396A
PH25396A PH33383A PH33383A PH25396A PH 25396 A PH25396 A PH 25396A PH 33383 A PH33383 A PH 33383A PH 33383 A PH33383 A PH 33383A PH 25396 A PH25396 A PH 25396A
Authority
PH
Philippines
Prior art keywords
protein
activity
produce
expression
compounds
Prior art date
Application number
PH33383A
Other languages
English (en)
Inventor
Nils Ulrik Bang
Robert John Beckmann
Stanley Richard Jaskunas Jr
Sheila Parks Little
George Louis Long
Mei-Huei Lai
Robert Frank Santerre
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24811674&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PH25396(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of PH25396A publication Critical patent/PH25396A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6464—Protein C (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21069—Protein C activated (3.4.21.69)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/822—Microorganisms using bacteria or actinomycetales
    • Y10S435/832—Bacillus
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/822—Microorganisms using bacteria or actinomycetales
    • Y10S435/848—Escherichia
    • Y10S435/849—Escherichia coli
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/822—Microorganisms using bacteria or actinomycetales
    • Y10S435/886—Streptomyces

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
PH33383A 1985-02-08 1986-02-04 Vectors, compounds for expression of human protein c PH25396A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/699,967 US4775624A (en) 1985-02-08 1985-02-08 Vectors and compounds for expression of human protein C

Publications (1)

Publication Number Publication Date
PH25396A true PH25396A (en) 1991-06-03

Family

ID=24811674

Family Applications (1)

Application Number Title Priority Date Filing Date
PH33383A PH25396A (en) 1985-02-08 1986-02-04 Vectors, compounds for expression of human protein c

Country Status (21)

Country Link
US (2) US4775624A (de)
EP (1) EP0191606B2 (de)
JP (6) JPH0698002B2 (de)
KR (1) KR860006546A (de)
CN (1) CN86100868A (de)
AT (1) ATE85079T1 (de)
AU (1) AU593538B2 (de)
CA (1) CA1341073C (de)
DE (2) DE3687584T4 (de)
DK (2) DK55486D0 (de)
ES (2) ES8704206A1 (de)
GR (1) GR860334B (de)
HU (1) HU211032B (de)
IE (1) IE59423B1 (de)
IL (1) IL77781A (de)
MY (1) MY103018A (de)
NZ (1) NZ215031A (de)
PH (1) PH25396A (de)
PT (1) PT81959B (de)
SG (1) SG50631A1 (de)
ZA (1) ZA86780B (de)

Families Citing this family (101)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4775624A (en) * 1985-02-08 1988-10-04 Eli Lilly And Company Vectors and compounds for expression of human protein C
US5981216A (en) * 1985-04-01 1999-11-09 Alusuisse Holdings A.G. Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
DE3684546D1 (de) * 1985-04-22 1992-04-30 Genetics Inst Herstellung mit hoher leistung des aktivfaktors ix.
US4968626A (en) * 1985-08-15 1990-11-06 Board Of Reagents Of The University Of Washington DNA sequence coding for protein C
US5516650A (en) * 1985-06-27 1996-05-14 Zymogenetics, Inc. Production of activated protein C
DE3688900T3 (de) * 1985-06-27 1998-06-10 Univ Washington Expression von Protein C.
US4959318A (en) * 1985-06-27 1990-09-25 Zymogenetics, Inc. Expression of protein C
USRE38981E1 (en) * 1985-08-15 2006-02-14 Board Of Regents Of The University Of Washington DNA sequence coding for protein C
US5618715A (en) * 1985-12-20 1997-04-08 Oncogen Limited Partnership Oncostatin M and novel compositions having anti-neoplastic activity
GB8607502D0 (en) * 1986-03-26 1986-04-30 Antibioticos Sa Penicillium chrysogenum
CA1318619C (en) * 1986-04-09 1993-06-01 Brian William Grinnell Method of using eukaryotic expression vectors comprising the bk virus enhancer
US5550036A (en) 1986-04-09 1996-08-27 Eli Lilly And Company Method for co-amplification of human protein C genes in human cells
JPS63105675A (ja) * 1986-10-23 1988-05-10 Green Cross Corp:The ヒトウロキナ−ゼの製造方法
WO1988005466A2 (en) * 1987-01-15 1988-07-28 Codon Tandem gene eukaryotic expression vectors
JPH03501921A (ja) * 1987-05-18 1991-05-09 インテグレイテッド・ジェネティクス・インク 改良タンパク質分子、並びにその製造及び活性化方法
DK260987D0 (da) * 1987-05-22 1987-05-22 Nordisk Gentofte Fremgangsmaade til fremstilling af et humant protein samt dna-sekvens til anvendelse ved udoevelse af fremgangsmaaden
JPS6445398A (en) * 1987-08-13 1989-02-17 Kowa Co Antithrombin-binding substance monoclonal antibody, hybridoma producing said antibody and method for purifying and measuring thrombin-binding substance utilizing said monoclonal antibody
US5084274A (en) * 1987-11-17 1992-01-28 Scripps Clinic And Research Foundation Inhibition of arterial thrombotic occlusion or thromboembolism
IL87171A (en) * 1987-11-23 1995-08-31 Monsanto Co ANDC of human tissue factor inhibitor
US4992373A (en) * 1987-12-04 1991-02-12 Eli Lilly And Company Vectors and compounds for direct expression of activated human protein C
US5196322A (en) * 1987-12-28 1993-03-23 Eli Lilly And Company Vectors and compounds for expression of zymogen forms of human protein C
ZA889497B (en) * 1987-12-28 1990-08-29 Lilly Co Eli Vectors and compounds for expression of zymogen forms of human protein c
US5009889A (en) * 1987-12-31 1991-04-23 Oklahoma Medical Research Foundation Treatment of dysfunctional vascular endothelium using activated protein C
JPH01285196A (ja) * 1988-05-11 1989-11-16 Chisso Corp 発光蛋白エクオリンの製造法
GB8819607D0 (en) * 1988-08-17 1988-09-21 Wellcome Found Novel combination
CA1332049C (en) * 1988-10-07 1994-09-20 Eli Lilly And Company Eukaryotic expression
US5047335A (en) * 1988-12-21 1991-09-10 The Regents Of The University Of Calif. Process for controlling intracellular glycosylation of proteins
US6423313B1 (en) * 1988-12-30 2002-07-23 Oklahoma Medical Research Foundation Inhibition of tumor growth by blockade of the protein C system
US5147638A (en) * 1988-12-30 1992-09-15 Oklahoma Medical Research Foundation Inhibition of tumor growth by blockade of the protein C system
US5120537A (en) * 1989-06-14 1992-06-09 Oklahoma Medical Research Foundation Factor xa based anticoagulant compositions
SE464135B (sv) * 1989-07-14 1991-03-11 Kabivitrum Ab Foerfarande foer bestaemning av funktionell aktivitet av fritt protein s eller protein c i ett plasmaprov
US5358932A (en) * 1989-12-29 1994-10-25 Zymogenetics, Inc. Hybrid protein C
ES2113878T3 (es) * 1989-12-29 1998-05-16 Zymogenetics Inc Proteina c hibrida.
US5225537A (en) * 1989-12-29 1993-07-06 Zymogenetics, Inc. Methods for producing hybrid phospholipid-binding proteins
DE69131292T2 (de) * 1990-01-29 1999-09-30 Zymogenetics, Inc. Antikoagulierende proteine
IL97311A0 (en) * 1990-02-23 1992-05-25 Lilly Co Eli Vectors and compounds for expression of glycosylation mutants of human protein c
US5270178A (en) * 1990-02-23 1993-12-14 Eli Lilly And Company Vectors and compounds for expression of zymogen forms of human protein C
IL97312A (en) 1990-02-23 1999-01-26 Lilly Co Eli A method of generating a polypeptide in an eukaryotic vector AND recombinant surrogate cell containing an enhanced transcriptional control unit based on the primary late adenovirus coefficient
US5571786A (en) * 1990-08-16 1996-11-05 Immuno Aktiengesellschaft Use of protein C or the activation peptide of protein C for preparing a pharmaceutical preparation
US5831141A (en) * 1991-01-11 1998-11-03 United States Of America As Represented By The Department Of Health And Human Services Expression of a heterologous polypeptide in mammary tissue of transgenic non-human mammals using a long whey acidic protein promoter
US6262336B1 (en) 1991-01-11 2001-07-17 American Red Cross Expression of a heterologous protein C in mammary tissue of transgenic animals using a long whey acidic protein promoter
AU1228592A (en) * 1991-01-11 1992-08-17 American Red Cross Expression of active human protein c in mammary tissue of transgenic animals
US5965789A (en) * 1991-01-11 1999-10-12 American Red Cross Engineering protein posttranslational modification by PACE/furin in transgenic non-human mammals
US5817788A (en) * 1991-02-28 1998-10-06 Zymogenetics, Inc. Modified factor VII
US5861374A (en) * 1991-02-28 1999-01-19 Novo Nordisk A/S Modified Factor VII
US5997864A (en) 1995-06-07 1999-12-07 Novo Nordisk A/S Modified factor VII
US5788965A (en) * 1991-02-28 1998-08-04 Novo Nordisk A/S Modified factor VII
US5833982A (en) 1991-02-28 1998-11-10 Zymogenetics, Inc. Modified factor VII
AT397615B (de) * 1991-05-14 1994-05-25 Immuno Ag Arzneimittel enthaltend protein c
US6039944A (en) * 1992-02-28 2000-03-21 Zymogenetics, Inc. Modified Factor VII
MY110664A (en) * 1992-05-21 1999-01-30 Lilly Co Eli Protein c derivatives
DE4320294A1 (de) * 1993-06-18 1994-12-22 Immuno Ag Verwendung von humanem Protein C zur Verhinderung und Behandlung von Thrombozytenablagerungen
CN1103815C (zh) * 1993-11-12 2003-03-26 吉里德科学公司 凝血酶突变体
US7060484B1 (en) 1993-11-12 2006-06-13 Gilead Sciences, Inc. Polypeptides and coagulation therapy
US5618714A (en) * 1993-12-15 1997-04-08 Eli Lilly And Company Methods for producing protein C
WO1995024929A2 (en) 1994-03-15 1995-09-21 Brown University Research Foundation Polymeric gene delivery system
WO1995030429A1 (en) * 1994-05-04 1995-11-16 Board Of Trustees Of The University Of Arkansas Novel ophthalmologic uses of protein c
AT403167B (de) * 1994-11-14 1997-11-25 Immuno Ag Selektion und expression von fremdproteinen mittels eines selektions-amplifikations-systems
US6017697A (en) 1994-11-14 2000-01-25 Eli Lilly And Company Excitatory amino acid receptor protein and related nucleic acid compounds
US6211142B1 (en) * 1995-03-10 2001-04-03 Genentech, Inc. Compositions comprising gas6 polypeptides and articles of manufacture comprising the same
CN1127568C (zh) 1996-10-16 2003-11-12 津莫吉尼蒂克斯公司 成纤维细胞生长因子同系物
EP0946715B1 (de) * 1996-11-08 2006-03-29 Oklahoma Medical Research Foundation Verwendung eines modifizierten protein-c
US20060127387A1 (en) * 1997-04-22 2006-06-15 Zikria Bashir A Compositions based on polysaccharides and protein C and methods of using the same for preventing and treating sepsis and other conditions
US6630137B1 (en) * 1997-04-28 2003-10-07 Eli Lilly And Company Activated protein C formulations
EA002149B1 (ru) * 1997-04-28 2001-12-24 Эли Лилли Энд Компани Улучшенные способы приготовления активированного белка с
WO1998055142A1 (en) * 1997-06-05 1998-12-10 Eli Lilly And Company Methods for treating thrombotic disorders
HUP0001237A3 (en) * 1997-10-20 2002-01-28 Lilly Co Eli Methods for treating vascular disorders
US6815533B1 (en) 1998-07-31 2004-11-09 Eli Lilly And Company Cryogranulation of activated protein C
EP1124573A1 (de) 1998-10-22 2001-08-22 Eli Lilly And Company Behandlung von sepsis
EP1128842B1 (de) 1998-11-13 2006-03-15 Eli Lilly And Company Verwendung von menschliche protein c zur herstellung eines arzneimittels zur behandlung von heparininduzierter thrombozytopenie
DE69906568T2 (de) 1998-11-20 2004-02-12 Eli Lilly And Co., Indianapolis Behandlung von hämorrhagischem virusfieber mit protein c
DK1133314T3 (da) 1998-11-23 2003-04-14 Lilly Co Eli Protein C til behandling af seglcellesygdom og thalassæmi
JP2003514545A (ja) * 1999-11-19 2003-04-22 イーライ・リリー・アンド・カンパニー プロテインｃ誘導体
US7204981B2 (en) * 2000-03-28 2007-04-17 Eli Lilly And Company Methods of treating diseases with activated protein C
AU2001262939A1 (en) 2000-05-24 2001-12-03 Eli Lilly And Company Formulations and use of activated protein c and protein c zymogen for treating hypercoagulable states
JP4071105B2 (ja) * 2000-10-18 2008-04-02 マキシゲン・エイピーエス プロテインｃまたは活性化プロテインｃ様分子
US6933367B2 (en) * 2000-10-18 2005-08-23 Maxygen Aps Protein C or activated protein C-like molecules
US20040198652A1 (en) * 2001-04-24 2004-10-07 Carter J. Paul Methods and compositions for preventing and treating septic shock and endotoxemia
JP2004535461A (ja) * 2001-07-19 2004-11-25 ディーエムアイ バイオサイエンシズ インコーポレイテッド プロテインｃの不活性化を抑制するための銅キレート剤の使用
CA2462396A1 (en) 2001-09-19 2003-03-27 Oklahoma Medical Research Foundation Treatment of sepsis with tafi
US20030073636A1 (en) * 2001-09-19 2003-04-17 Oklahoma Medical Research Foundation Method of treating diabetes
US7308303B2 (en) * 2001-11-01 2007-12-11 Advanced Bionics Corporation Thrombolysis and chronic anticoagulation therapy
EP1485121A4 (de) * 2002-03-08 2007-11-07 Lilly Co Eli Aktivierte protein-c-formulierungen
WO2004056309A2 (en) 2002-12-05 2004-07-08 Socratech L.L.C. Neuroprotective activity of activated protein c is independent of its anticoagulant activity
WO2004060395A1 (ja) * 2002-12-27 2004-07-22 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute 悪性腫瘍治療における生命予後の改善剤
US20070142272A1 (en) * 2003-01-24 2007-06-21 Zlokovic Berislav V Neuroprotective activity of activated protein c independent of its anticoagulant activity
US7498305B2 (en) * 2003-07-08 2009-03-03 The Scripps Research Institute Activated protein C variants with normal cytoprotective activity but reduced anticoagulant activity
US9192657B2 (en) 2003-07-08 2015-11-24 The Scripps Research Institute Activated protein C variants with normal cytoprotective activity but reduced anticoagulant activity
EP2325318A1 (de) 2004-02-13 2011-05-25 Novozymes A/S Proteasevarianten
WO2006014839A2 (en) * 2004-07-23 2006-02-09 The University Of Rochester Activated protein c inhibits undesirable effects of plasminogen activator in the brain
WO2006136033A1 (en) * 2005-06-23 2006-12-28 The University Of British Columbia Coagulation factor iii polymorphisms associated with prediction of subject outcome and response to therapy
ZA200800251B (en) * 2005-06-24 2009-04-29 Drugrecure Aps Airway administration of tissue factor pathway inhibitor in inflammatory conditions affecting the respiratory track
EP2041338A4 (de) * 2006-06-09 2009-09-30 Univ British Columbia Interferon-gamma-polymorphismen als indikatoren des patientenergebnisses bei schwerkranken patienten
WO2008048646A1 (en) * 2006-10-18 2008-04-24 Socratech L.L.C. Use of human protein c with altered glycosylation and sialic acid content as a medicament
CA2668187A1 (en) * 2006-10-31 2008-06-19 The Scripps Research Institute Dosing regimen of activated protein c and variants having reduced anticoagulant activity
EP2242875A4 (de) * 2008-01-15 2012-04-04 Univ British Columbia Protein-c-rs2069915 als reaktionsprädiktor für überlebensrate und verabreichung einer aktivierten protein-c- oder protein-c-ähnlichen verbindung
RU2469093C2 (ru) * 2008-12-19 2012-12-10 Общество с ограниченной ответственностью "Лаборатория медицинской биотехнологии" (ООО "ЛМБТ") ЭКСПРЕССИОННАЯ ПЛАЗМИДНАЯ ДНК pCID-PROC, КОДИРУЮЩАЯ ПРОТЕИН С ЧЕЛОВЕКА, И КЛЕТОЧНАЯ ЛИНИЯ DG-CID-PROC-1, ПРОДУЦИРУЮЩАЯ РЕКОМБИНАНТНЫЙ ПРОТЕИН С ЧЕЛОВЕКА
WO2012068519A2 (en) 2010-11-19 2012-05-24 Sirius Genomics Inc. Markers associated with response to activated protein c administration, and uses thereof
CN104394883B (zh) 2012-07-04 2017-05-31 悉尼大学 炎性皮肤病症的治疗
CA2946028C (en) 2014-04-16 2022-10-11 Zz Biotech Llc Treatment of abnormal cutaneous scarring
WO2023119230A1 (en) 2021-12-22 2023-06-29 L'oreal Coagulation pathway and nicotinamide-adenine dinucleotide pathway modulating compositions and methods of their use

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4438032A (en) * 1981-01-30 1984-03-20 The Regents Of The University Of California Unique T-lymphocyte line and products derived therefrom
US4382028A (en) * 1982-07-19 1983-05-03 Monsanto Company Separation of plasma proteins from cell culture systems
AU572125B2 (en) * 1983-03-17 1988-05-05 Mabco Limited Monoclonal antibodies with specificity for crosslinked fibrin and their diagnotic uses
US4775624A (en) * 1985-02-08 1988-10-04 Eli Lilly And Company Vectors and compounds for expression of human protein C
DE3684546D1 (de) * 1985-04-22 1992-04-30 Genetics Inst Herstellung mit hoher leistung des aktivfaktors ix.
AU603768B2 (en) * 1985-07-04 1990-11-29 Kanegafuchi Kagaku Kogyo Kabushiki Kaisha Lymphotoxin dna, lymphotoxin expression vector, lymphotoxin resistant cell, transformant with lymphotoxin expression vector and process for preparing lymphotoxin

Also Published As

Publication number Publication date
ES8707764A1 (es) 1987-08-16
US5151268A (en) 1992-09-29
JP2873153B2 (ja) 1999-03-24
JPH08317794A (ja) 1996-12-03
PT81959A (en) 1986-03-01
JP2854283B2 (ja) 1999-02-03
EP0191606A2 (de) 1986-08-20
DE3687584T3 (de) 2001-05-03
US4775624A (en) 1988-10-04
CN86100868A (zh) 1986-09-24
GR860334B (en) 1986-06-05
DE3687584T2 (de) 1993-05-27
DK55486D0 (da) 1986-02-05
JPH10327876A (ja) 1998-12-15
EP0191606B1 (de) 1993-01-27
JPH0759190B2 (ja) 1995-06-28
EP0191606A3 (en) 1987-01-21
JPH0698002B2 (ja) 1994-12-07
JPH06189782A (ja) 1994-07-12
IE860328L (en) 1986-08-08
ATE85079T1 (de) 1993-02-15
PT81959B (pt) 1988-07-01
AU593538B2 (en) 1990-02-15
IE59423B1 (en) 1994-02-23
ZA86780B (en) 1987-09-30
JPH06220092A (ja) 1994-08-09
IL77781A (en) 1991-08-16
HUT40168A (en) 1986-11-28
ES557100A0 (es) 1987-08-16
DE3687584T4 (de) 2001-07-26
DE3687584D1 (de) 1993-03-11
JP2854282B2 (ja) 1999-02-03
KR860006546A (ko) 1986-09-13
JPH09273A (ja) 1997-01-07
CA1341073C (en) 2000-08-08
ES8704206A1 (es) 1987-03-16
EP0191606B2 (de) 2001-01-24
MY103018A (en) 1993-04-30
ES551761A0 (es) 1987-03-16
JP2992002B2 (ja) 1999-12-20
SG50631A1 (en) 1998-07-20
NZ215031A (en) 1988-02-29
DK55086D0 (da) 1986-02-05
DK55086A (da) 1986-08-09
JPS61205487A (ja) 1986-09-11
HU211032B (en) 1995-09-28
AU5325686A (en) 1986-08-14

Similar Documents

Publication Publication Date Title
PH25396A (en) Vectors, compounds for expression of human protein c
ES2005073A6 (es) Procedimiento para preparar benzamidas y bencenoacetamidas
GR3004568T3 (de)
GR3033103T3 (en) Peptidyl compounds and their therapeutic use as inhibitors of metalloproteinases
ATE227587T1 (de) Kombinierte verwendung von hyaluronsäure und therapeutischen wirkstoffen zur verbesserung des therapeutischen effekts
HU9204029D0 (en) Proteolytic enzym inhibitors
AU6998787A (en) Transglutaminase inhibitors
DE3687429D1 (de) Gamma-ifn als wirkstoff zur hemmung (verhinderung) von abbauprozessen im knochen.
IL91276A0 (en) Pharmaceutical compositions containing alpha-amino boronic acid derivatives,for the prophylaxis and treatment of virus diseases
ES2002398A6 (es) Procedimiento para preparar nuevas enolamidas
DK0408461T3 (da) Protein med uratoxidase-aktivitet, rekombinant gen, der koder for proteinet, samt ekspressionsvektor, mikroorganismer og transformerede celler
MA20919A1 (fr) Procede de preparation d'inhibiteurs de l'enzyme de conversion de l'angiotensine
IE890612L (en) Inhibitors of lysyl oxidase
IT1188729B (it) Procedimento e dispositivo per il trattamento di prodotti di uovo,o relativi composti,per prolungare la durata dei prodotti medesimi
GR920100519A (el) Ενώσεις.